Vivani Medical receives approval for Australia's first-in-human clinical trial of GLP-1 (exenatide) implant for obesity treatment.

Vivani Medical has received approval to conduct a first-in-human clinical trial in Australia for its GLP-1 (exenatide) implant aimed at treating obesity. The trial, named LIBERATE-1, will assess the implant's safety and efficacy compared to semaglutide, with the possibility of biannual administration. The trial is set to begin in late 2024, with data expected by 2025, which may aid regulatory submissions in other regions, including the U.S.

September 26, 2024
5 Articles

Further Reading